阅读说明：本技术 一种用于治疗肾虚和前列腺炎的药物组合物及其制备方法 (A pharmaceutical composition for treating kidney deficiency and prostatitis, and its preparation method ) 是由 张峰铄 周鲁帝 于 2021-09-17 设计创作，主要内容包括：本发明公开了一种用于治疗肾虚和前列腺炎的药物组合物及其制备方法,涉及治疗肾虚的药物技术领域,所述的用于治疗肾虚和前列腺炎的药物组合物包括如下重量份数的原料组分：南非醉茄萃取物45-55份、黑马卡萃取粉15-25份、透纳叶萃取粉15-25份、人参0.8-1.2份、山药0.8-1.2份、黄精0.8-1.2份、牛蒡0.8-1.2份、牡蛎0.8-1.2份、牡蛎肽0.8-1.2份、牛蒡提取物精氨酸0.8-1.2份、非活性成分2.5-3.5份；所述的非活性成分为蔗糖素、柠檬酸和二氧化硅。本发明提供的用于治疗肾虚和前列腺炎的药物组合物采用天然中药和食物作为原料组分、无副作用、可以从根本上治疗肾虚、针对腰膝酸软、畏寒怕热、性冷淡、勃起障碍、性交时间短、前腺炎等症状显著效果。(The invention discloses a pharmaceutical composition for treating kidney deficiency and prostatitis and a preparation method thereof, and relates to the technical field of medicaments for treating kidney deficiency, wherein the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 45-55 parts of Nanfeijoa extract, 15-25 parts of black maca extract powder, 15-25 parts of tonna leaf extract powder, 0.8-1.2 parts of ginseng, 0.8-1.2 parts of Chinese yam, 0.8-1.2 parts of rhizoma polygonati, 0.8-1.2 parts of burdock, 0.8-1.2 parts of oyster peptide, 0.8-1.2 parts of burdock extract arginine and 2.5-3.5 parts of inactive ingredients; the inactive ingredients are sucralose, citric acid and silicon dioxide. The pharmaceutical composition for treating kidney deficiency and prostatitis provided by the invention adopts natural traditional Chinese medicines and food as raw material components, has no side effect, can fundamentally treat kidney deficiency, and has obvious effects on symptoms such as soreness and weakness of waist and knees, intolerance of cold and heat, frigidity, erectile dysfunction, short sexual intercourse time, prostatitis and the like.)

1. A pharmaceutical composition for treating kidney deficiency and prostatitis is characterized in that: the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 45-55 parts of Nanfeijoa extract, 15-25 parts of black maca extract powder, 15-25 parts of tonna leaf extract powder, 0.8-1.2 parts of ginseng, 0.8-1.2 parts of Chinese yam, 0.8-1.2 parts of rhizoma polygonati, 0.8-1.2 parts of burdock, 0.8-1.2 parts of oyster peptide, 0.8-1.2 parts of burdock extract arginine and 2.5-3.5 parts of inactive ingredients; the inactive ingredients are sucralose, citric acid and silicon dioxide.

2. The pharmaceutical composition for treating kidney deficiency and prostatitis according to claim 1, wherein the pharmaceutical composition comprises: the inactive components are sucralose, citric acid and silicon dioxide, and the weight part ratio of the sucralose to the citric acid to the silicon dioxide is 1: 1: 1.

3. the pharmaceutical composition for treating kidney deficiency and prostatitis according to claim 2, wherein: the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 50 parts of a south African nightshade extract, 20 parts of black maca extract powder, 20 parts of tonna leaf extract powder, 1 part of ginseng, 1 part of Chinese yam, 1 part of rhizoma polygonati, 1 part of burdock, 1 part of oyster peptide, 1 part of burdock extract arginine and 3 parts of inactive ingredients.

4. The pharmaceutical composition for treating kidney deficiency and prostatitis according to claim 2, wherein: the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 45 parts of Withania somnifera extract, 15 parts of black maca extract powder, 15 parts of tonna leaf extract powder, 0.8 part of ginseng, 0.8 part of Chinese yam, 0.8 part of rhizoma polygonati, 0.8 part of burdock, 0.8 part of oyster peptide, 0.8 part of burdock extract arginine and 2.5 parts of inactive ingredients.

5. The pharmaceutical composition for treating kidney deficiency and prostatitis according to claim 2, wherein: the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 55 parts of kava extract, 25 parts of black maca extract powder, 25 parts of tonna leaf extract powder, 1.2 parts of ginseng, 1.2 parts of Chinese yam, 1.2 parts of rhizoma polygonati, 1.2 parts of burdock, 1.2 parts of oyster peptide, 1.2 parts of burdock extract arginine and 3.5 parts of inactive ingredients.

6. The process for preparing a pharmaceutical composition for treating kidney deficiency and prostatitis as claimed in any one of claims 1 to 5, wherein the pharmaceutical composition comprises: the preparation method comprises the following steps: s1, respectively cleaning ginseng, Chinese yam, rhizoma polygonati, burdock and oyster, draining, drying, crushing, sieving and mixing to obtain a mixture; s2, adding the Withania somnifera extract powder, the black maca extract powder, the tonna leaf extract powder, the oyster peptide and the burdock extract arginine into the mixture prepared in the step S1, and uniformly mixing to prepare the composition.

7. The preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis according to claim 6, wherein the pharmaceutical composition comprises the following components: in step S1, the drying is carried out at 60-80 ℃ for 24 hours.

8. The preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis according to claim 6, wherein the pharmaceutical composition comprises the following components: in step S1, the sieving is 200 mesh sieving.

Technical Field

The invention relates to the technical field of medicaments for treating kidney deficiency, in particular to a medicinal composition for treating kidney deficiency and prostatitis and a preparation method thereof.

Background

The kidney deficiency of modern men is caused by various factors such as busy work, increasing living pressure, lack of exercise and the like. Kidney deficiency refers to the deficiency of kidney essence, qi, yin and yang, which is classified into deficiency of kidney yin and deficiency of kidney yang. The kidney deficiency can cause symptoms of waist soreness, leg weakness, cold limbs, intolerance of cold, night sweat, sweating due to deficiency, dizziness, tinnitus, sexual function deterioration, erectile dysfunction, prostatitis, etc.

Due to the lack of knowledge and concept problems, many men with kidney deficiency are shy of hospitalization and abuse drugs, such as: poor quality drugs on the market such as Viagra, Wan ai Ke, Indian balsam, etc. The Viagra and the Wanaike contain western medicine components such as nafil, and cannot fundamentally treat kidney deficiency, and severe side effects can damage organs such as heart, liver and kidney, and can cause rash, urinary system infection and aggravate impotence; the indian oil can achieve the effect of prolonging the sexual intercourse time only through local anesthesia, and cannot really tonify the kidney and improve the sexual function.

At present, no pharmaceutical composition which adopts natural traditional Chinese medicines and food as raw material components, has no side effect, and can fundamentally treat kidney deficiency, improve sexual function, improve erection, prolong sexual intercourse time and treat prostatitis exists in the market.

Disclosure of Invention

Aiming at the defects in the prior art, the invention provides a pharmaceutical composition for treating kidney deficiency and prostatitis, which is characterized in that: the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 45-55 parts of Nanfeijoa extract, 15-25 parts of black maca extract powder, 15-25 parts of tonna leaf extract powder, 0.8-1.2 parts of ginseng, 0.8-1.2 parts of Chinese yam, 0.8-1.2 parts of rhizoma polygonati, 0.8-1.2 parts of burdock, 0.8-1.2 parts of oyster peptide, 0.8-1.2 parts of burdock extract arginine and 2.5-3.5 parts of inactive ingredients; the inactive ingredients are sucralose, citric acid and silicon dioxide.

Preferably, the inactive ingredients are sucralose, citric acid and silicon dioxide in a weight ratio of 1: 1: 1.

further preferably, the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 50 parts of a south African nightshade extract, 20 parts of black maca extract powder, 20 parts of tonna leaf extract powder, 1 part of ginseng, 1 part of Chinese yam, 1 part of rhizoma polygonati, 1 part of burdock, 1 part of oyster peptide, 1 part of burdock extract arginine and 3 parts of inactive ingredients.

Further preferably, the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 45 parts of Withania somnifera extract, 15 parts of black maca extract powder, 15 parts of tonna leaf extract powder, 0.8 part of ginseng, 0.8 part of Chinese yam, 0.8 part of rhizoma polygonati, 0.8 part of burdock, 0.8 part of oyster peptide, 0.8 part of burdock extract arginine and 2.5 parts of inactive ingredients.

Further preferably, the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight: 55 parts of kava extract, 25 parts of black maca extract powder, 25 parts of tonna leaf extract powder, 1.2 parts of ginseng, 1.2 parts of Chinese yam, 1.2 parts of rhizoma polygonati, 1.2 parts of burdock, 1.2 parts of oyster peptide, 1.2 parts of burdock extract arginine and 3.5 parts of inactive ingredients.

The preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following steps: s1, respectively cleaning ginseng, Chinese yam, rhizoma polygonati, burdock and oyster, draining, drying, crushing, sieving and mixing to obtain a mixture; s2, adding the Withania somnifera extract powder, the black maca extract powder, the tonna leaf extract powder, the oyster peptide and the burdock extract arginine into the mixture prepared in the step S1, and uniformly mixing to prepare the composition.

Preferably, in step S1, the drying is performed at 60-80 ℃ for 24 hours.

Preferably, in step S1, the sieving is 200 mesh sieving.

The invention has the beneficial effects that:

(1) the pharmaceutical composition for treating kidney deficiency and prostatitis provided by the invention adopts natural traditional Chinese medicines and food as raw material components, has no side effect, can fundamentally treat kidney deficiency, and has obvious effects on symptoms such as soreness and weakness of waist and knees, intolerance of cold and heat, frigidity, erectile dysfunction, short sexual intercourse time, prostatitis and the like.

(2) The pharmaceutical composition for treating kidney deficiency and prostatitis provided by the invention has quick effect, can take effect after being continuously used for 2-3 days, and has obvious effect after being used for 7-15 days.

(3) The preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis provided by the invention is simple to operate, stable in technology, easy to obtain raw materials, excellent in effect of the prepared product and high in commercial value.

Detailed Description

Hereinafter, embodiments of the present invention will be described in detail. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.

It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.

Example 1

The pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight:

50 parts of a south African nightshade extract, 20 parts of black maca extract powder, 20 parts of tonna leaf extract powder, 1 part of ginseng, 1 part of Chinese yam, 1 part of rhizoma polygonati, 1 part of burdock, 1 part of oyster peptide, 1 part of burdock extract arginine and 3 parts of inactive ingredients.

The inactive components are sucralose, citric acid and silicon dioxide, and the weight part ratio of the sucralose to the citric acid to the silicon dioxide is 1: 1: 1.

the preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following steps:

s1, respectively cleaning ginseng, Chinese yam, rhizoma polygonati, burdock and oyster, draining, drying, crushing, sieving and mixing to obtain a mixture;

s2, adding the Withania somnifera extract powder, the black maca extract powder, the tonna leaf extract powder, the oyster peptide and the burdock extract arginine into the mixture prepared in the step S1, and uniformly mixing to prepare the composition.

In step S1, the drying is performed for 24 hours under 60 f.

In step S1, the sieving is 200 mesh sieving.

Example 2

The pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight:

45 parts of Withania somnifera extract, 15 parts of black maca extract powder, 15 parts of tonna leaf extract powder, 0.8 part of ginseng, 0.8 part of Chinese yam, 0.8 part of rhizoma polygonati, 0.8 part of burdock, 0.8 part of oyster peptide, 0.8 part of burdock extract arginine and 2.5 parts of inactive ingredients.

The inactive components are sucralose, citric acid and silicon dioxide, and the weight part ratio of the sucralose to the citric acid to the silicon dioxide is 1: 1: 1.

the preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following steps:

s1, respectively cleaning ginseng, Chinese yam, rhizoma polygonati, burdock and oyster, draining, drying, crushing, sieving and mixing to obtain a mixture;

s2, adding the Withania somnifera extract powder, the black maca extract powder, the tonna leaf extract powder, the oyster peptide and the burdock extract arginine into the mixture prepared in the step S1, and uniformly mixing to prepare the composition.

In step S1, the drying is performed for 24 hours under 60 f.

In step S1, the sieving is 200 mesh sieving.

Example 3

The pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following raw material components in parts by weight:

55 parts of kava extract, 25 parts of black maca extract powder, 25 parts of tonna leaf extract powder, 1.2 parts of ginseng, 1.2 parts of Chinese yam, 1.2 parts of rhizoma polygonati, 1.2 parts of burdock, 1.2 parts of oyster peptide, 1.2 parts of burdock extract arginine and 3.5 parts of inactive ingredients.

The inactive components are sucralose, citric acid and silicon dioxide, and the weight part ratio of the sucralose to the citric acid to the silicon dioxide is 1: 1: 1.

the preparation method of the pharmaceutical composition for treating kidney deficiency and prostatitis comprises the following steps:

s1, respectively cleaning ginseng, Chinese yam, rhizoma polygonati, burdock and oyster, draining, drying, crushing, sieving and mixing to obtain a mixture;

s2, adding the Withania somnifera extract powder, the black maca extract powder, the tonna leaf extract powder, the oyster peptide and the burdock extract arginine into the mixture prepared in the step S1, and uniformly mixing to prepare the composition.

In step S1, the drying is performed for 24 hours under 60 f.

In step S1, the sieving is 200 mesh sieving.

Test examples

Effect test of the pharmaceutical composition for treating kidney deficiency and prostatitis prepared in example 1 of the present invention

Test subjects: 250 married male patients with local erectile dysfunction are selected, the age of the patients is 30-50 years, and the course of the disease is 10-30 months.

The test subject met the diagnosis standard of erectile dysfunction in the guidelines for diagnosis and treatment of erectile dysfunction (2016 edition); the course of disease is more than 6 months; the relationship between the patient and the wife is stable for at least 6 months. Patients with low testosterone level, genital anatomical deformity, severe cardiovascular and cerebrovascular diseases, diabetes, and severe hepatic and renal insufficiency are excluded.

Grouping tests:

patients were randomized into 125 control and 125 treatment groups. Wherein patients in the treatment group are 30-50 years old, with a mean age (31.9 + -5.8) of age; the course of disease is 8-29 months, and the average course of disease (16.2 +/-4.9 months). Patients in the control group were 30-50 years old, with the mean age (31.2 ± 6.2) years old; the course of disease is 8-30 months, and the average course of disease (15.8 +/-5.1) months. The difference between the age and the disease course of the two groups of patients has no statistical significance and is comparable.

The test method comprises the following steps:

the sildenafil citrate tablets are orally taken 3-5 hours before sexual intercourse of a control group, 1 tablet/time (specification is 25 mg/tablet), and 4 times per week;

the treatment group takes the pharmaceutical composition for treating kidney deficiency and prostatitis 3-5 h before sexual intercourse, 3g once a day and 4 times a week.

The two groups of patients are prohibited from taking the nitrate medicine, and the curative effect and adverse reaction condition are counted after taking for 2 weeks.

Criteria for therapeutic effect

The effect is shown: the penis erection hardness is good, the sexual intercourse is completed, and the score of an international index questionnaire (IIEF-5) of the erection function is more than 21 points;

the method has the following advantages: the penis erection function is improved compared with the prior art, and the IIEF-5 score is improved by more than 10 points;

and (4) invalidation: the penile erection had no significant change than before, and the IIEF-5 score was changed by < 5 points or no change.

Analysis of total effective rate (effective + effective)/total number of cases results

Observation index

IIEF-5 scoring is carried out on two groups of patients before and after treatment, and the total number of the patients is 5, wherein each patient is divided into 0-5 points, the 0 point is the worst, the 5 point is the best, and the full score is 25. An ILEF-5 score of less than or equal to 21 is classified as erectile dysfunction, and an ILEF-5 score of more than 21 is classified as no erectile dysfunction. Meanwhile, the two groups of patients are scored according to an Erection Quality Scale (EQS), 15 questions are counted, each question is 0-4 points, the full score is 60 points, and the higher the score is, the better the erection effect is. The onset time and duration of intercourse after the patient took the drug were statistically analyzed.

And (3) test results: specific results are shown in tables 1 and 2.

TABLE 1

	Number of cases/person	Show effect/human	Effective/human	Invalid/human	Total effective rate/%)
						Treatment group	125	43	35	42	62.4
Control group	125	75	41	9	92.8

The total effective rates of the two groups are statistically processed and have significant difference (p is less than 0.05).

TABLE 2

The total effective rates of the two groups are statistically processed and have significant difference (p is less than 0.05).

As can be seen from tables 1 and 2, the pharmaceutical composition for treating kidney deficiency and prostatitis provided in example 1 of the present invention can significantly improve erectile dysfunction, prolong intercourse time, and achieve an effective rate as high as 92.8%.

Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.